These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 29396429)

  • 1. Activin-dependent signaling in fibro/adipogenic progenitors causes fibrodysplasia ossificans progressiva.
    Lees-Shepard JB; Yamamoto M; Biswas AA; Stoessel SJ; Nicholas SE; Cogswell CA; Devarakonda PM; Schneider MJ; Cummins SM; Legendre NP; Yamamoto S; Kaartinen V; Hunter JW; Goldhamer DJ
    Nat Commun; 2018 Feb; 9(1):471. PubMed ID: 29396429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
    Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
    J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
    Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
    Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
    Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV-Mediated Targeting of the Activin A-ACVR1
    Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
    Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
    J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis.
    Stanley A; Heo SJ; Mauck RL; Mourkioti F; Shore EM
    J Bone Miner Res; 2019 Oct; 34(10):1894-1909. PubMed ID: 31107558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
    Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
    J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
    Wang H; Shore EM; Pignolo RJ; Kaplan FS
    Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1
    Maruyama R; Nguyen Q; Roshmi RR; Touznik A; Yokota T
    Nucleic Acid Ther; 2022 Jun; 32(3):185-193. PubMed ID: 35085461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.
    Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC
    J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.
    Srinivasan D; Arostegui M; Goebel EJ; Hart KN; Aykul S; Lees-Shepard JB; Idone V; Hatsell SJ; Economides AN
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.
    Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P
    Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW; Peck SH; Kaplan FS; Shore EM
    Dev Biol; 2021 Feb; 470():136-146. PubMed ID: 33217406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
    Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
    J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.